Goldman Sachs
TMCI icon

Goldman Sachs’s Treace Medical Concepts TMCI Stock Holding History

Goldman Sachs’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48,000
Closed -$908K – 6718
2022
Q1 		$908K Buy
+48,000
New +$933K ﹤0.01% 4894

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs's TMCI Position: Q2 2026 in Review

Goldman Sachs increased its Treace Medical Concepts (TMCI) stake by 27% in Q2 2026, buying an estimated $287K and bringing the position to 492,116 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #4698.

Goldman Sachs first reported a position in TMCI in Q2 2021 and has held it in 19 quarters since. The position peaked at $4.51M in Q4 2023. 116 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • Goldman Sachs held 492,116 shares of Treace Medical Concepts worth $1.96M as of Q2 2026.
  • Goldman Sachs bought 104,431 Treace Medical Concepts shares in Q2 2026, an estimated $287K.
  • Treace Medical Concepts made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4698 holding.
  • Goldman Sachs first reported a position in Treace Medical Concepts in Q2 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Treace Medical Concepts position peaked at $4.51M in Q4 2023.
  • 116 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.